CD138和乙酰肝素酶在膀胱癌中的表达和临床意义

目的：探讨膀胱癌中CD138和乙酰盯素酶的表达水平及其与膀胱癌发生、发展、复发和转移的关系。方法：应用免疫组化Envision二步法研究58例膀胱中CD138和乙酰肝素酶的表达水平。结果：CD138在膀胱癌中的阳性表达35例（60.3％），其表达率与肿瘤的病理分级、临床分期、复发和淋巴结转移无相关性（P〉0.05）。乙酰肝素酶在膀胱癌中阳性表达22例（37.9％），其表达率与肿瘤的病理分级、临床分期、复发和淋巴结转移有相关性（P〈O.01）。CD138和乙酰肝素酶表达呈正相关（P〈0.01），其共同表达与肿瘤的病理分级、临床分期、复发和淋巴结转移有相关性（P〈0.05）。结论：CD138和乙酰肝素酶蛋白的共同表达能成为膀胱癌发生和发展的预后参数。

Expression and clinical significance of CD138 and heparanase in bladder carcinoma

Objective:To study the expression of CD138 and heparanase in bladder carcinoma and the relationship with its development,progression,recrudescence and metastasis.Methods:Immunohistochemical technique was used to detect the expression of CD138 and heparanase in 58 cases of bladder carcinoma.Results:The positive protein expression of CD138 was 60.3%(35/58).The CD138 protein expression was not correlated with the pathological type,clinical stage,recrudescence and lymph node metastasis(P>0.05).The positive protein expression of heparanase was 37.9%(22/58).The heperanase protein expression was correlated with the pathological type,clinical stage,recrudescence and lymph node metastasis(P<0.05).The positive protein co-expression of CD138 and heperanase was correlated with the pathological type,clinical stage,recrudescence and lymph node metastasis(P<0.05).Conclusions:Co-expression of CD138 and heparanase protein might serve as marker for the prognosis of bladder carcinoma.